RxDoctor Payments Data

Sahar Fathallah Shaykh, MD

Pediatric Nephrology · Birmingham, ALNPI 1033187505

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,500 of the $4,577 with a category attached, or 98.3%. Bayer accounts for 98.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $4,535 and has fallen 99.5% since, to $24 in 2025.

$4,577in general payments, 2019–2025

Across 6 payments — averaging $762.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$4K
  • Apellis Pharmaceuticals, Inc.$24
  • Recordati_rare_diseases_inc.$21
  • Baxter Healthcare$18
  • CMP Pharma, Inc.$14
$456,217in research payments, 2019–2025

Across 45 payments — averaging $10,138 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$135K
  • Genentech, Inc.$88K
  • Akebia Therapeutics Inc$66K
  • Cormedix Inc.$52K
  • Vifor Fresenius Medical Care Renal Pharma Ltd.$40K
  • Bayer$33K
  • plus $42K from 2 others

What the payments were for

  • Consulting fees$4,50098%
  • Food & beverage$772%

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer2$4,500
Apellis Pharmaceuticals, Inc.1$24
Recordati_rare_diseases_inc.1$21
Baxter Healthcare1$18
CMP Pharma, Inc.1$14

How this compares

Too few pediatric nephrology providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$15,070
Medicare patients
21
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate13$1,338
Lisinopril12$16
Amlodipine Besylate11$10

Paid to pharmacies, not to this prescriber.

Other pediatric nephrology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →